Who is sponsoring NCT03315676?

NCT03315676 is sponsored by Shinshu University.

What drugs are being tested in NCT03315676?

Interventions in NCT03315676: Oral Bonoprazan, Oral Esomeprazol.

What condition does NCT03315676 study?

NCT03315676 studies Gastrointestinal Erosions and/or Ulcers.

Is NCT03315676 still recruiting?

NCT03315676 is currently status unknown. Last updated 21 September 2021.

Last reviewed 2021-09-21 · How we verify

NCT03315676

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Efficacy of Proton Pump Inhibitors in Gastrointestinal Erosions and/or Ulcers

Status unknown Phase 2 Last updated 21 September 2021

What this trial tests

Phase 2 trial testing Oral Bonoprazan in Gastrointestinal Erosions and/or Ulcers in 124 participants. Status unknown.

Timeline

1 November 2017

Primary endpoint
21 November 2022

4 September 2025

Quick facts

Lead sponsor	Shinshu University
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	124
Start date	1 November 2017
Primary completion	21 November 2022
Estimated completion	4 September 2025
Sites	1 location across Japan

Drugs / interventions tested

Oral Bonoprazan — full drug profile →
Oral Esomeprazol — full drug profile →

Conditions studied

Gastrointestinal Erosions and/or Ulcers — all drugs for Gastrointestinal Erosions and/or Ulcers →

Sponsor

Shinshu University

Who can join

Adults 20 to 99, any sex, with Gastrointestinal Erosions and/or Ulcers. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study is to collect the data of clinical efficacy and safety after the usage of bonoprazon and esomeprazole when the patients take NSAIDs more than 2 weeks and have gastrointestinal symptoms who have had gastrointestinal erosions and/or ulcers in the past.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shinshu University trials

Trials by the same sponsor.

NCT05469659 — Effect of Tofogliflozin on UACR Compared to Metformin Hydrochloride in Diabetic Kidney Disease (TRUTH-DKD) · Phase 2 · recruiting
NCT03784261 — Usefulness of Non TNF Usage in RA Patients · Phase 2 · unknown
NCT03755193 — Examination of Efficacy and Safety of Other Anti-Resorption Drugs After 2-year-Denosumab Therapy in Japanese Osteoporosi · Phase 2 · recruiting
NCT03755466 — Examination of Efficacy and Safety of Baricitinib in RA Patients · Phase 2 · unknown
NCT03702140 — Examination How the Administration Period of Teriparatide Affects Bone Metabolism and Bone Mineral Density Prior to Deno · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03315676 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shinshu University
Last refreshed: 21 September 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03315676.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing